19 unknown. 19 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Unknown 19 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 3 | Unknown 3 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis Ixekizumab - Guttate Psoriasis | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-01 | 2025-02-10 |
| Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis HB0034 - Generalized Pustular Psoriasis | Phase 2 / Phase 3 | Unknown | Shanghai Huaota Biopharmaceutical Co., Ltd. | 33 | 2024-09-02 | 2025-02-14 |
| Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral - Psoriatic Arthritis | Phase 2 | Unknown | Hansoh BioMedical R&D Company | 160 | 2024-02-26 | 2024-07-18 |
| A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets - Psoriasis | Phase 2 | Unknown | Hansoh BioMedical R&D Company | 120 | 2023-09-28 | 2023-12-06 |
| A Study of QY101 Ointment in Subjects With Plaque Psoriasis QY101Placebo/QY101 ointment - Psoriasis | Phase 2 | Unknown | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 160 | 2023-05-17 | 2023-12-19 |
| Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis Umbilical cord mesenchymal stem cells - Mesenchymal Stromal Cells, Psoriasis | Phase 1 / Phase 2 | Unknown | Guangdong Provincial Hospital of Traditional Chinese Medicine | 5 | 2021-08-31 | 2021-02-09 |
| A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo - Psoriasis | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 139 | 2021-04-01 | 2022-11-08 |
| Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis PSORI-CM01 formula, Gu Ben Hua Yu formula, adipose-derived multipotent mesenchymal stem cells - Traditional Chinese Medicine, Drug Effect | Phase 1 / Phase 2 | Unknown | Guangdong Provincial Hospital of Traditional Chinese Medicine | 16 | 2021-03-17 | 2023-08-24 |
| Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement Tofacitinib 5 MG Oral Tablet [Xeljanz], Placebo oral tablet - Psoriatic Arthritis, Spondylitis | Phase 2 | Unknown | Charite University, Berlin, Germany | 80 | 2020-08-04 | 2022-07-26 |
| Psoriasis、Indigo Naturalis、Chinese Medicine Medicated Bath paper mulberry leaf, Triamcinolone (Encort-A) 0.1%15g/Tube - Psoriasis | Phase 2 | Unknown | China Medical University Hospital | 30 | 2019-10-05 | 2019-10-16 |
| Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial Turmeric Extract, Turmeric Extract in Olive oil, Petrolatum - Psoriasis | Phase 2 / Phase 3 | Unknown | Zagazig University | 50 | 2019-09-01 | 2019-08-28 |
| Chinese Herbal Medicine for Psoriasis Vulgaris: a Real World Study Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, Oral Chinese Herbal Medicine according with syndrome differentiation therapy, Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy - Psoriasis | Phase 2 | Unknown | Shanghai Yueyang Integrated Medicine Hospital | 2000 | 2019-06-01 | 2019-05-08 |
| Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand Phototherapy - Vitiligo | Phase 2 | Unknown | University of British Columbia | 30 | 2013-02-01 | 2015-07-02 |
| A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 IDP-118 Low Strength, IDP-118 High Strength - Plaque Psoriasis | Phase 1 / Phase 2 | Unknown | Dow Pharmaceutical Sciences | 60 | 2012-06-01 | 2013-04-25 |
| Vaccination Against Influenza H1N1 in Rheumatic Diseases Focetria (Monovalent MF59-Adjuvanted vaccine) - Influenza, Rheumatic Diseases | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 400 | 2009-11-01 | 2009-11-03 |
| Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis IP10.C8 - Psoriasis | Phase 2 | Unknown | Immune Technologies & Medicine GmbH | 24 | 2009-01-01 | 2009-01-19 |
| 99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity 99mTc-anti-TNF-alpha Scintigraphy - Psoriatic Arthritis, Arthritis | Phase 2 | Unknown | Universidade Federal do Rio de Janeiro | 50 | 2009-01-01 | 2016-05-27 |
| Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis Methotrexate - Fingernail Psoriasis | Phase 2 | Unknown | MediQuest Therapeutics | 83 | 2007-10-01 | 2009-02-10 |
| CYA Versus MMF for Treatment of Moderate-Severe Psoriasis. Cyclosporine A versus mycophenolate mofetil for psoriasis - Psoriasis | Phase 2 | Unknown | University Hospital Muenster | 50 | 2000-05-01 | 2006-10-05 |
Arthritis, Psoriatic (4) · Arthritis (1) · Arthritis, Rheumatoid (1) · Drug-Related Side Effects and Adverse Reactions (1) · Eczema (1) · Guttate Psoriasis (1) · Inflammation (1) · Influenza, Human (1) · Rheumatic Diseases (1) · Sacroiliitis (1) · Spondylitis (1) · Vitiligo (1)
Skin Diseases (19) · Skin Diseases, Papulosquamous (19) · Skin and Connective Tissue Diseases (19) · Bone Diseases (4) · Joint Diseases (4) · Musculoskeletal Diseases (4) · Spinal Diseases (4) · Spondylarthritis (4) · Spondylarthropathies (4) · Arthritis (3) · Spondylitis (3) · Connective Tissue Diseases (2) · Infections (2) · Autoimmune Diseases (1)
tofacitinib (2) · Betamethasone (1) · Methotrexate (1) · Olive Oil (1) · Petrolatum (1) · Phototherapy (1) · Tablets (1) · Triamcinolone (1) · calcipotriene (1) · focetria (1) · ixekizumab (1) · turmeric extract (1)
Guangdong Provincial Hospital of Traditional Chinese Medicine (2) · Hansoh BioMedical R&D Company (2) · Charite University, Berlin, Germany (1) · China Medical University Hospital (1) · Dow Pharmaceutical Sciences (1) · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (1) · Immune Technologies & Medicine GmbH (1) · MediQuest Therapeutics (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Huaota Biopharmaceutical Co., Ltd. (1) · Shanghai Yueyang Integrated Medicine Hospital (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · Tel-Aviv Sourasky Medical Center (1) · Universidade Federal do Rio de Janeiro (1) · University Hospital Muenster (1)
China (8) · Germany (2) · Brazil (1) · Canada (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Aijun Chen (1) · Bianca Gutfilen, PhD (1) · Chao Ci (1) · Chao Ji (1) · Chuanjian Lu, PhD (1) · Chunlei Zhang (1) · Chunshui Yu (1) · Denis Poddubnyy, Prof (1) · Fengming Hu (1) · Guoqiang Zhang (1) · Hagar Nofal (1) · Harvey Lui, MD, FRCPC (1) · Hejian Zou, PhD (1) · Hui-Man Cheng (1) · Jia Zhou (1)
PMID 21425247, PMID 31930095, PMID 33306625, PMID 34785545, PMID 36189747